Bio-Rad Laboratories ( (BIO) ) has shared an announcement.

Bio-Rad Laboratories (NYSE:BIO) executives said the company finished 2025 within revised guidance for revenue and operating ...

Rad's (BIO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Bio-Rad Labs (BIO) has delivered a -3.13% change over the past year, with a 52-week range between 211.43 and 343.12. What Is the Average Daily Trading Volume of Bio-Rad Labs (BIO)? The average daily ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 Earnings Call Transcript February 12, 2026 Bio-Rad Laboratories, Inc. misses on earnings expectations. Reported EPS is $2.51 EPS, expectations were $2.57.

Bio-Rad Laboratories BIO is something of a rarity: a small-cap company with a wide economic moat. The company develops products and solutions for the clinical diagnostics and life sciences industries, ...

Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...

Bio-Rad trades at nearly 30 times forward earnings despite recent losses, reflecting expectations for a turnaround as its ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt ...

Bio-Rad remains undervalued, but persistent end-market headwinds and limited core growth drivers temper my conviction. BIO's valuation is heavily influenced by its substantial Sartorius stake, and the ...

During the quarter, Bio-Rad recognized a substantial change in the fair market value of its investment in Sartorius AG, ...

Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this time, I ...